General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

• Published in: Haematologica (Roma) Vol. 108; no. 7; pp. 1758 - 1767
• Main Authors: Gökbuget, Nicola, Ihrig, Kristina, Stadler, Michael, Stelljes, Matthias, Elmaagacli, Ahmet, Starck, Michael, Raffel, Simon, Stoltefuss, Andrea, Viardot, Andreas, Kreuzer, Karl-Anton, Heidenreich, Daniela, Renzelmann, Andrea, Wäsch, Ralph, Topp, Max S., Ritter, Barbara, Reimer, Peter, Beck, Joachim, Westermann, Jörg, Wendelin, Knut, Alakel, Nael, Hanoun, Maher, Serve, Hubert, Hoelzer, Dieter
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.07.2023; Ferrata Storti Foundation
• Subjects: Acute Lymphoblastic Leukemia; Adolescent; Adult; Child; Comorbidity; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Retrospective Studies; Survivors; Young Adult
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2022.281820

Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cannot be transferred. The GMALL analyzed the health status in survivors of adult ALL retrospectively. Physicians answered a questionnaire on general condition (Eastern Cooperative Oncology Group [ECOG] status) and comorbidity or syndrome occurrence observed after treatment. Five hundred and thirty-eight patients with a median age of 29 (range, 15-64) years at diagnosis were analyzed, median follow-up was 7 (range, 3-24) years. Thirty-one percent had received SCT. ECOG status was 0-1 in 94%, 34% had not developed significant comorbidities. Most frequent comorbidities involved the neurologic system (27%), endocrine system (20%), skin (18%), graft-versus-host-disease (15%), cardiac system (13%), fatigue (13%). SCT impacted ECOG status and comorbidity occurrence significantly. ECOG 0-1 was observed in 86% of SCT and 98% of non-SCT patients (P<0.0001); comorbidity was observed in 87% and 57% respectively (P<0.0001). Our analysis elucidates the spectrum of comorbidities in cured adult ALL patients, with higher risk for transplanted patients, providing stimulations for the design of adequate aftercare programs. Overall, a large proportion of non-SCT patients achieved unrestricted general condition. The data provide a reference for new patient-centered endpoints in future trials.